Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: filgrastim
INDICATION: neutropenia
DATE: 10/10/2014
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
